BACKGROUND: Morphology highlighted by diffusion weighted imaging (DWI) is the basis of whole-body MRI (wbMRI). The aim of this study was to analyze current knowledge on the diagnostic performance of wbMRI in the pretreatment staging of patients with lymphoma. METHODS: A search for original articles reporting the diagnostic performance (sensitivity, specificity) of pretreatment (first staging or staging in relapsed patients after complete remission) wbMRI in nodal and extranodal involvement by extracranial lymphoma and the agreement of stage by the Cotswolds-modified Ann Arbor classification in adult patients compared to the reference standard (PET/CT or enhanced reference standard) was conducted in PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov. RESULTS: Altogether 15 studies with 519 patients were included in the meta-analysis. The pooled sensitivity and specificity for nodal involvement were 0.93 (95% CI: 0.90 to 0.96) and 0.99 (95% CI: 0.98 to 1.00). For nodal staging, most studies used the size criterion of 10 mm in the short diameter (n=10) and the absence of prominent fatty hilum (n=4). Restricted diffusion on diffusion-weighted imaging as a sign of nodal involvement was either not used (n=5), used for detection (n=4), semi-quantitatively (n=4), or quantitatively (n=1). Only one study (7) relied solely on restricted diffusion as the main criterion for nodal involvement. The pooled sensitivity and specificity for extranodal involvement were 0.89 (95% CI: 0.79 to 0.98) and 0.99 (95% CI: 0.99 to 1.00). Seven studies considered diffuse splenic involvement when its long or vertical axis was greater than 13 cm regardless of the patient's physiognomy. The pooled agreement in staging (Cohen's kappa) was almost perfect (0.90, 95% CI: 0.84 to 0.95). DISCUSSION: The sensitivity and specificity of wbMRI in the assessment of the nodal and extranodal involvement by lymphoma is high. The agreement of wbMRI with the reference standard is almost perfect.

Department of Anaesthesiology Resuscitation and Intensive Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Hematology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Institute of Nuclear Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Zobrazit více v PubMed

Lewis WD, Lilly S, Jones KL. Lymphoma: Diagnosis and Treatment. Am Fam Physician 2020;101:34-41. PubMed

McCarten KM, Nadel HR, Shulkin BL, Cho SY. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatr Radiol 2019;49:1545-64. 10.1007/s00247-019-04529-8 PubMed DOI

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059-68. 10.1200/JCO.2013.54.8800 PubMed DOI PMC

Meignan M, Hutchings M, Schwartz LH. Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. Oncologist 2015;20:890-5. 10.1634/theoncologist.2015-0036 PubMed DOI PMC

Alessandrino F, DiPiro PJ, Jagannathan JP, Babina G, Krajewski KM, Ramaiya NH, Giardino AA. Multimodality imaging of indolent B cell lymphoma from diagnosis to transformation: what every radiologist should know. Insights Imaging 2019;10:25. 10.1186/s13244-019-0705-y PubMed DOI PMC

Johnson SA, Kumar A, Matasar MJ, Schöder H, Rademaker J. Imaging for Staging and Response Assessment in Lymphoma. Radiology 2015;276:323-38. 10.1148/radiol.2015142088 PubMed DOI

Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, Porpaczy E, Weber M, Pinker-Domenig K, Berzaczy D, Hoffmann M, Sillaber C, Jaeger U, Müllauer L, Simonitsch-Klupp I, Dolak W, Gaiger A, Ubl P, Lukas J, Raderer M. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res 2014;20:2984-93. 10.1158/1078-0432.CCR-13-3355 PubMed DOI

Donners R, Yiin RSZ, Koh DM, De Paepe K, Chau I, Chua S, Blackledge MD. Whole-body diffusion-weighted MRI in lymphoma-comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals. Quant Imaging Med Surg 2021;11:3549-61. 10.21037/qims-21-50 PubMed DOI PMC

Tsuji K, Kishi S, Tsuchida T, Yamauchi T, Ikegaya S, Urasaki Y, Fujiwara Y, Ueda T, Okazawa H, Kimura H. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT. J Magn Reson Imaging 2015;41:1601-7. 10.1002/jmri.24714 PubMed DOI

Balbo-Mussetto A, Cirillo S, Bruna R, Gueli A, Saviolo C, Petracchini M, Fornari A, Lario CV, Gottardi D, De Crescenzo A, Tarella C. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma. Clin Radiol 2016;71:271-9. 10.1016/j.crad.2015.11.018 PubMed DOI

Lin C, Luciani A, Itti E, El-Gnaoui T, Vignaud A, Beaussart P, Lin SJ, Belhadj K, Brugières P, Evangelista E, Haioun C, Meignan M, Rahmouni A. Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 2010;20:2027-38. 10.1007/s00330-010-1758-y PubMed DOI

Abdulqadhr G, Molin D, Aström G, Suurküla M, Johansson L, Hagberg H, Ahlström H. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol 2011;52:173-80. 10.1258/ar.2010.100246 PubMed DOI

Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011;197:W384-91. 10.2214/AJR.10.5692 PubMed DOI

van Ufford HM, Kwee TC, Beek FJ, van Leeuwen MS, Takahara T, Fijnheer R, Nievelstein RA, de Klerk JM. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. AJR Am J Roentgenol 2011;196:662-9. 10.2214/AJR.10.4743 PubMed DOI

Stéphane V, Samuel B, Vincent D, Joelle G, Remy P, Francois GG, Jean-Pierre T. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol 2013;82:2011-7. 10.1016/j.ejrad.2013.05.042 PubMed DOI

Ferrari C, Minoia C, Asabella AN, Nicoletti A, Altini C, Antonica F, Ficco M, Guarini A, Maggialetti N, Rubini G. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma. Hell J Nucl Med 2014;17 Suppl 1:40-9. PubMed

Azzedine B, Kahina MB, Dimitri P, Christophe P, Alain D, Claude M. Whole-body diffusion-weighted MRI for staging lymphoma at 3.0T: comparative study with MR imaging at 1.5T. Clin Imaging 2015;39:104-9. 10.1016/j.clinimag.2014.06.017 PubMed DOI

Albano D, Patti C, La Grutta L, Agnello F, Grassedonio E, Mulè A, Cannizzaro G, Ficola U, Lagalla R, Midiri M, Galia M. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol 2016;85:313-8. 10.1016/j.ejrad.2015.12.006 PubMed DOI

Gamal GH. Whole-body magnetic resonance/diffusion-weighted sequence with background signal suppression (WB-MR/DWIBS) vs. 18F-FDG PET/CT in diagnosis of lymphoma. Egyptian Journal of Radiology and Nuclear Medicine 2020;51:210. 10.1186/s43055-020-00290-3 DOI

Kharuzhyk S, Zhavrid E, Dziuban A, Sukolinskaja E, Kalenik O. Comparison of whole-body MRI with diffusion-weighted imaging and PET/CT in lymphoma staging. Eur Radiol 2020;30:3915-23. 10.1007/s00330-020-06732-w PubMed DOI

Latifoltojar A, Duncan MKJ, Klusmann M, Sidhu H, Bainbridge A, Neriman D, Fraioli F, Lambert J, Ardeshna KM, Punwani S. Whole Body 3.0 T Magnetic Resonance Imaging in Lymphomas: Comparison of Different Sequence Combinations for Staging Hodgkin's and Diffuse Large B Cell Lymphomas. J Pers Med 2020;10:284. 10.3390/jpm10040284 PubMed DOI PMC

Hong GS, Chae EJ, Ryu JS, Chae SY, Lee HS, Yoon DH, Suh C. Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients. Cancer Imaging 2021;21:5. 10.1186/s40644-020-00371-6 PubMed DOI PMC

Michielsen K, Dresen R, Vanslembrouck R, De Keyzer F, Amant F, Mussen E, Leunen K, Berteloot P, Moerman P, Vergote I, Vandecaveye V. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer 2017;83:88-98. 10.1016/j.ejca.2017.06.010 PubMed DOI

Wang D, Huo Y, Chen S, Wang H, Ding Y, Zhu X, Ma C. Whole-body MRI versus 18F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis. Onco Targets Ther 2018;11:3597-608. 10.2147/OTT.S148189 PubMed DOI PMC

Stecco A, Buemi F, Iannessi A, Carriero A, Gallamini A. Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma. Leuk Lymphoma 2018;59:2546-56. 10.1080/10428194.2018.1434881 PubMed DOI

Chow KU, Luxembourg B, Seifried E, Bonig H. Spleen Size Is Significantly Influenced by Body Height and Sex: Establishment of Normal Values for Spleen Size at US with a Cohort of 1200 Healthy Individuals. Radiology 2016;279:306-13. 10.1148/radiol.2015150887 PubMed DOI

Voltin CA, Mettler J, Grosse J, Dietlein M, Baues C, Schmitz C, Borchmann P, Kobe C, Hellwig D. FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma-An Updated Overview. Cancers (Basel) 2020;12:601. 10.3390/cancers12030601 PubMed DOI PMC

Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients